-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
September 16, 2020 /--- In a recent study, Monash University and Lava Therapeutics detailed a new immuno-oncology method that could be used for potential cancer treatment.
study was co-authored by Dr. Roeland Lameris of UMC amsterdam.
The study, published in the journal Nature Cancer and co-led by Professor Jamie Rossjohn and Dr Adam Shahine, ARC Prize-winners at the Monash Institute for Biomedical Discovery, highlights synergies between antibody fragments, known as nanoantibodies, that not only help connect two key immune cellular subjects, but also use their interactions to enhance the body's immune response to cancer.
(Photo: www.pixabay.com) These antibody fragments, called nanoantibodies, fight tumor samples in patients with multiple myeloma and acute myeloid leukemia by targeting the interaction between molecules known as CD1d and natural killer T-cells (NKT) in a stable and long-lasting manner.
new findings will provide a model for potentially new and effective treatments for a variety of cancers.
Monash University used the Australian Synchrotron to provide detailed resolution-derived structures to understand how nanoantibodies work on immune cells in cancer models.
Rossjohn said: "We were able to accurately visualize how nanoantibodies identified CD1d and NKT TCR at the same time, providing a molecular basis for their anti-tumor properties.
"By targeting and enhancing the natural immune cells inherent in humans, such as NKT cells and gamma-t cells, we believe our approach can eventually be translated into immunotherapy for a wide range of cancer adaptations," said Hans van der Vliet, Chief Scientific Officer of Lava Therapeutics.
, co-first author of the study, said: "This collaboration paves the way for the rational development of improved treatments for multiple cancers.
.com Source: Novel immune-oncology approach for potential cancer treatment Original source: A single-domain bispecific antibody targeting CD1d and the NKT T-cell receptor induces a potent antitumor response, Nature Cancer (2020). DOI: 10.1038/s43018-020-00111-6,
